The prevalence of psychiatric symptoms before the diagnosis of Parkinson's disease
in a nationwide cohort: A comparison to patients with cerebral infarction
National Brain Research Program(2017-2-1 NKP-2017-00002)
(EFOP-3.6.3-VEKOP-16-2017-00009)
Objectives Psychiatric symptoms (PS) can be non-motor features in Parkinson's disease
(PD) which are common even in the prodromal, untreated phase of the disease. Some
PS, especially depression and anxiety recently became known predictive markers for
PD. Our objective was to explore retrospectively the prevalence of PS before the diagnosis
of PD. Methods In the framework of the Hungarian Brain Research Program we created
a database from medical and medication reports submitted for reimbursement purposes
to the National Health Insurance Fund in Hungary, a country with 10 million inhabitants
and a single payer health insurance system. We used record linkage to evaluate the
prevalence of PS before the diagnosis of PD and compared that with patients with ischemic
cerebrovascular lesion (ICL) in the period between 2004-2016 using ICD-10 codes of
G20 for PD, I63-64 for ICL and F00-F99 for PS. We included only those patients who
got their PD, ICL and psychiatric diagnosis at least twice. Results There were 79
795 patients with PD and 676 874 patients with ICL. Of the PD patients 16% whereas
of those with ischemic cerebrovascular lesion 9.7% had a psychiatric diagnosis before
the first appearance of PD or ICL (p<0.001) established in psychiatric care at least
twice. The higher rate of PS in PD compared to ICL remained significant after controlling
for age and gender in logistic regression analysis. The difference between PD and
ICL was significant for Mood disorders (F30-F39), Organic, including symptomatic,
mental disorders (F00-F09), Neurotic, stress-related and somatoform disorders (F40-F48)
and Schizophrenia, schizotypal and delusional disorders (F20-F29) diagnosis categories
(p<0.001, for all). Discussion The higher rate of psychiatric morbidity in the premotor
phase of PD may reflect neurotransmitter changes in the early phase of PD.